OCX's Business Model
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://oncocyte.com |
| CEO (Chief Executive Officer) | Joshua Riggs |
| Number of Employees | |
| IPO date | December 30, 2015 |
OCX Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 15 Cushing |
| City | Irvine |
| State | CA |
| Phone | 949 409 7600 |
| Zip Code | 92618 |
| Other Identifiers | |
| CIK | 0001642380 |
| ISIN | US68235C2061 |
| CUSIP | 68235C107 |
| Open | 2.82 |
| Previous Close | 2.73 |
| Volume | 100.6 Thou. |
| Average Volume | 76.06 Thou. |
| Day’s Range | 2.82 – 3.2 |
| 52 Week Range | 1.922-4.75 |
| MA (50) | 3.0328 |
| MA (200) | 2.80248 |
| Market Cap | 91.52 Mil. |
| Shares Out. | 28.6 Mil. |
| Earnings Date | Aug 06, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
